A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) (HATCH)

Antengene

Status and phase: Terminated; Phase 2; Phase 1

Conditions: Myelodysplastic Syndrome

Treatments: Drug: ATG-016

Study type: Interventional

Funder types: Industry

Identifiers

NCT04691141

ATG-016-MDS-001

Details and patient eligibility

About

This is a Phase Ⅰ/II, Open-label Study to Investigate the Pharmacokinetics, Safety, and Efficacyof ATG 016 Monotherapy in IPSS-R Intermediate Risk and above Myelodysplastic Syndrome (MDS) Patients after Failure of Hypomethylating Agent (HMA)-based Therapy.

Full description

This is a Phase Ⅰ/II, Open-label Study to Investigate the Pharmacokinetics, Safety, and Efficacyof ATG 016 Monotherapy in IPSS-R Intermediate Risk and above Myelodysplastic Syndrome (MDS) Patients after Failure of Hypomethylating Agent (HMA)-based Therapy. In Phase I: approximately 15 to 21 subjects and Phase II: approximately 44 subjects; approximately 59 to 65 subjects will be enrolled totally in this study.

Enrollment: 15 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.
2. ≥18 years of age, males or females.
3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
4. A life expectancy longer than 3 months in the opinion of the investigator at the screening.
5. Male subjects (Including those who have received vasectomy) must agree to use condoms during sex with a woman of childbearing age and have no plans to impregnate the woman throughout the study and for 3 months following the last dose after the date of signing the ICF.

Exclusion criteria

1. History of central nervous system (CNS) involvement.
2. Toxicity from prior antitumor therapy did not return to Grade 1 or baseline (Except for alopecia, neutropenia, anemia, and thrombocytopenia. For neutrophils, hemoglobin, and platelets, please follow Exclusion Criteria No. 5).
3. History of human immunodeficiency virus (HIV) infection.
4. History of severe bleeding disorder, such as hemophilia A, hemophilia B, and vascular hemophilia.
5. History of allogeneic stem-cell transplantation.
6. Serious psychiatric or medical conditions that, in the opinion of the investigator, could interfere with treatment, compliance, or the ability to give consent.
7. Pregnant or lactating women.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

ATG-016

Experimental group

Description:

5 mg QD×Days 1-5/week will be the initial dose of this study.

Treatment:

Drug: ATG-016